<DOC>
	<DOCNO>NCT00682292</DOCNO>
	<brief_summary>To compare renal allograft rejection rate first year among high-immunological risk recipient patient receive either ATG anti-IL2R mAb daclizumab .</brief_summary>
	<brief_title>Daclizumab Versus Thymoglobulin Renal Transplant Recipients With High Immunological Risk</brief_title>
	<detailed_description>The objective randomized , multi-center trial directly compare ATG , Thymoglobulin , anti-CD25 mAb , daclizumab , high-risk , HLA-sensitized renal transplant population , order elucidate whether significant difference incidence acute rejection one year . Eligible patient randomize ( 1:1 ) receive either ATG ( 1.25 mg/kg/d day 0 day 7 ) daclizumab ( 1 mg/kg day 0 , 14 , 28 , 42 56 ) . Maintenance immunosuppression comprise tacrolimus , MMF prednisone . The study 's primary endpoint incidence biopsy-proven acute rejection one year .</detailed_description>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>1 . Third fourth renal graft 2 . Current antiHLA antibody equal 30 % last evaluation 3 . Peak antiHLA antibody equal 50 % last evaluation 4 . A second graft first lose within 2 year rejection . 5 . Patients give inform consent able understand scope study 1 . Transplantation live donor recipient multiple grafts patient already receive another ( nonrenal ) allograft . 2 . Transplantation nonheart beat donor 3 . Transplantation two kidney donor 4 . Patients generalized infection time transplantation 5 . Women childbearing age plan use efficient contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2004</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>Immunisation</keyword>
	<keyword>Acute rejection</keyword>
	<keyword>Induction therapy</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>Rejection sensitize renal transplant recipient</keyword>
</DOC>